BIO
A significant breakthrough in the quest for cost-effective Tissue Regeneration and Organogenesis
Significant costs associated to prolonged culture times has restricted in vitro tissue generation’s impact on billion-dollar tissue repair markets. A highly innovative Biomaterials Research team at NUIG has recently developed and patent-protected a simple, yet highly productive process for achieving a 20-fold improvement in matrix deposition within 48h of in vitro culture. This platform has the genuine potential to make the rapid production of a variety of tissue types a reality, including tendon, cornea, skin, peripheral nerve, cartilage and bone.
OsteoAnchor Technology
OsteoAnchor is an exciting development in the field of orthopaedic implants, such as hip and knee replacements, a market estimated to be worth $8.7 billion in the U.S and Europe.
Superior performance compared to competitors.
Multiple applications: hip, knee, shoulder, ankle.
Proven in vivo pre-clinical trial.
Patent applications filed in Europe, USA, Japan & China
Experienced team, with an impressive pipeline of Products.
Superior performance compared to competitors.
Multiple applications: hip, knee, shoulder, ankle.
Proven in vivo pre-clinical trial.
Patent applications filed in Europe, USA, Japan & China
Experienced team, with an impressive pipeline of Products.
Novel microRNA Biomarkers for detection of Luminal A breast cancer
Breast cancer is the most commonly diagnosed cancer in women both in the developed and the developing world. U.S. figures highlight that 1 in 8 (12%) women developing invasive breastcancer during their lifetime, with 17.4% of these dying as a result of the disease. Early diagnosis, aswell as accurate prognostication are critical to survival. Global health and potentially significant commercial rewards make high performance breast cancer biomarkers a valuable commodity. We have identified three novel miRNAs markers, miR-181a,miR-195 and miR652, with highly aberrant expression levels in women with breast cancer. Blood sample functionality is a particularly attractive feature from the perspective of the patient.
multi-channel conduit
Professor Pandit and his team at NUIG have developed and optimised a multi-channel conduit solution, which enables significantly improved guidance of nerve growth, repairing nerve gaps of up to 5cm in length. Such performance, along with the flexibility to control the rate of biodegradation, distinguishes this Multi-channel Conduit from any other conduit or solution currently on the market.
Bone Adhesive Technology
Bio-inspired polymeric adhesive for sternum closure
Polymer with improved transfection efficiency
At NUIG, we have recently developed a synthesis platform suitible for the production of specifically-designed cationic polymers. We have demonstrated these polymers to deliver improved transfection effeciency and cytotoxicity performance when compared to currently available gold standard gene delivery reagents. ‘NFBfect’ is an example of one such polymer.
Our platform is capable of synthesising polymers with impressive biodegradable properties [intracellular] and the specific addition of modifiable functional groups, making antibody (or indeed moieties of a variety of other applications) attachment a genuine prospect.
Our platform is capable of synthesising polymers with impressive biodegradable properties [intracellular] and the specific addition of modifiable functional groups, making antibody (or indeed moieties of a variety of other applications) attachment a genuine prospect.
Benzomacrolactone-based Peptide Mimetic Drugs
Insufficient pharmacokinetics following administration of the hormone somatostatin has led to the synthesis of both peptideand non -peptidemimetics. Such drugs are used for the treatment of arrange of conditions such as neuroendocrine tumors, acromegaly and increasingly, polycystic diseases of the liver and kidney. Treatments currently on the market including Sandostatin® (Novartis), with 2010 sales in the U.S. inexcess of $1.2billion*, and Somatuline® (Ipsen) are restricted in their requirement for parenteral administration.
Prof. Paul Murphy and his Research team at NUI Galway have recently identified the potential of using abenzomacrolact onescaffold to develop non peptidal somatost at inmimetics, with excellent activity and suitable for oral delivery.
Prof. Paul Murphy and his Research team at NUI Galway have recently identified the potential of using abenzomacrolact onescaffold to develop non peptidal somatost at inmimetics, with excellent activity and suitable for oral delivery.
